Newgenivf Exits XRP, Holds About 13,000 SOL; Losses Near $1.28M

NewGenIvf Group Limited, a Cayman-based IVF services provider listed on Nasdaq as NIVF, disclosed a completed 2025 XRP exit alongside a year-end holding of about 13,000 SOL and an unrealized valuation loss of roughly $1.28 million, according to Amendment No. 2 to its SEC Form F-1 filed September 10, 2026, framing the Newgenivf XRP exit as one leg of an opportunistic corporate-treasury program that ran entirely outside its core fertility business. The disclosure lands as public companies increasingly park idle cash in digital assets, yet NewGenIvf's filing is notable for the opposite reason: it shows a company that traded aggressively across four tokens through 2025 and ended the year holding only Solana, a concentration that turned a profitable trading year into a reported net crypto loss on paper. For related coverage, see Why Is NEAR Protocol (NEAR) Price Down Today?. What the filing confirms about the Newgenivf XRP exit NewGenIvf bought 146,432.14 XRP and sold the identical 146,432.14 XRP during the year ended December 31, 2025, leaving a year-end XRP balance of zero, per Note 8 of the company's Form F-1/A. The round-trip trade generated a realized gain of $10,849, meaning the Newgenivf XRP exit was completed at a profit, not a loss. The filing does not disclose the dates, prices, venues or counterparties for the XRP purchases and sales, nor whether the proceeds were redeployed into other tokens. Those transaction-level details sit outside the summarized activity table, so any inference that XRP sales funded Solana buying is unsupported by the document. XRP was one of four tokens NewGenIvf cycled through in 2025. The company bought and sold 8.77 BTC and 8.95 ETH over the year, booking realized gains of $12,569 on Bitcoin and $223 on Ethereum, with all BTC, ETH and XRP positions fully liquidated before December 31. XRP currently trades near $1.37 as of September 13, 2026, though that spot level has no bearing on the company's realized 2025 result. Ripple's own commercial footprint has kept expanding this year as it pushes deeper into Brazil payments and pursues a VASP license, a backdrop unrelated to NewGenIvf's passive trading. The reported SOL balance and its limits At December 31, 2025, NewGenIvf held 13,000.23 SOL, the only crypto position remaining on its balance sheet at year-end, according to the same filing. The activity table shows purchases of 46,118.55 SOL and sales of 33,118.32 SOL across 2025, netting to the reported year-end holding. The year-end SOL carried a cost basis of $2,906,222 and a fair value of $1,630,827, with the filing noting the assets were not subject to any contractual sale restrictions, pledges or lock-up arrangements as of that date, a detail Bitcoin.com's coverage of the filing did not address.